mdndhd_老虎社区_美港股上老虎

maltose123
2021-03-09

mdndhd

Novartis, Molecular Partners report positive early-stage results of COVID-19 antiviral therapy, ensovibep

Molecular Partners(OTCPK:MLLCF)and itscollaboratorNovartis(NYSE:NVS)announced initial results from t

Novartis, Molecular Partners report positive early-stage results of COVID-19 antiviral therapy, ensovibep

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":329457469,"tweetId":"329457469","gmtCreate":1615274030751,"gmtModify":1703486572250,"author":{"id":3578010145980988,"idStr":"3578010145980988","authorId":3578010145980988,"authorIdStr":"3578010145980988","name":"maltose123","avatar":"https://static.tigerbbs.com/071a4309a84b94aafc5b5d2c0fec025b","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>&nbsp;mdndhd</p></body></html>","htmlText":"<html><head></head><body><p>&nbsp;mdndhd</p></body></html>","text":"mdndhd","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/329457469","repostId":1168910610,"repostType":4,"repost":{"id":"1168910610","kind":"news","pubTimestamp":1615272511,"share":"https://www.laohu8.com/m/news/1168910610?lang=&edition=full","pubTime":"2021-03-09 14:48","market":"us","language":"en","title":"Novartis, Molecular Partners report positive early-stage results of COVID-19 antiviral therapy, ensovibep","url":"https://stock-news.laohu8.com/highlight/detail?id=1168910610","media":"seekingalpha","summary":"Molecular Partners(OTCPK:MLLCF)and itscollaboratorNovartis(NYSE:NVS)announced initial results from t","content":"<p>Molecular Partners(OTCPK:MLLCF)and itscollaboratorNovartis(NYSE:NVS)announced initial results from their ongoing phase 1 study of first tri-specificCOVID-19 antiviral treatment, ensovibep (MP0420), in healthy volunteers.</p><p>Healthy volunteers were randomized 3:1 to receive ensovibep or placebo, respectively.</p><p>Two dosing cohorts with 8 patients per dose cohort have been fully enrolled and received a single infusion of 3mg or 9mg per kilogram body weight.</p><p>In each of these cohorts, ensovibep was seen to be safe and well tolerated, with no significant adverse events reported.</p><p>Preliminary results showed extended exposure of the DARPin candidate in serum, with a half-life of 2-3 weeks.</p><p>These data support advanced plans for additional clinical work in positively diagnosed patients.</p><p>The companies looks forward to initiate phase 2/3 global registration study, early in Q2.</p><p>Per protocol, a third cohort at a 20mg per kilogram dose level has been planned.</p><p>In October 2020, Molecular Partners and Novartis collaborated to developtwo DARPin therapies for COVID-19.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis, Molecular Partners report positive early-stage results of COVID-19 antiviral therapy, ensovibep</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis, Molecular Partners report positive early-stage results of COVID-19 antiviral therapy, ensovibep\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-09 14:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3670544-novartis-molecular-partners-report-positive-early-stage-results-of-covid-19-antiviral-therapy-ensovibep><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Molecular Partners(OTCPK:MLLCF)and itscollaboratorNovartis(NYSE:NVS)announced initial results from their ongoing phase 1 study of first tri-specificCOVID-19 antiviral treatment, ensovibep (MP0420), in...</p>\n\n<a href=\"https://seekingalpha.com/news/3670544-novartis-molecular-partners-report-positive-early-stage-results-of-covid-19-antiviral-therapy-ensovibep\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVS":"诺华","MLLCF":"Molecular Partners AG"},"source_url":"https://seekingalpha.com/news/3670544-novartis-molecular-partners-report-positive-early-stage-results-of-covid-19-antiviral-therapy-ensovibep","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1168910610","content_text":"Molecular Partners(OTCPK:MLLCF)and itscollaboratorNovartis(NYSE:NVS)announced initial results from their ongoing phase 1 study of first tri-specificCOVID-19 antiviral treatment, ensovibep (MP0420), in healthy volunteers.Healthy volunteers were randomized 3:1 to receive ensovibep or placebo, respectively.Two dosing cohorts with 8 patients per dose cohort have been fully enrolled and received a single infusion of 3mg or 9mg per kilogram body weight.In each of these cohorts, ensovibep was seen to be safe and well tolerated, with no significant adverse events reported.Preliminary results showed extended exposure of the DARPin candidate in serum, with a half-life of 2-3 weeks.These data support advanced plans for additional clinical work in positively diagnosed patients.The companies looks forward to initiate phase 2/3 global registration study, early in Q2.Per protocol, a third cohort at a 20mg per kilogram dose level has been planned.In October 2020, Molecular Partners and Novartis collaborated to developtwo DARPin therapies for COVID-19.","news_type":1},"isVote":1,"tweetType":1,"viewCount":268,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":6,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}